VHL and kidney cancer.
Ohh
Michael
M
Dana-Farber Cancer Institute, Boston, MA, USA.
Kaelin
William G
WG
D000818:Animals; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D044842:Cullin Proteins; D000075065:Elongin; D005109:Extracellular Matrix / Q000378:metabolism; D005353:Fibronectins / Q000096:biosynthesis; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism; D008025:Ligases / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D006623:von Hippel-Lindau Disease / Q000235:genetics* / Q000378:metabolism
C105153:CUL2 protein, human; D018797:Cell Cycle Proteins; D044842:Cullin Proteins; D000075065:Elongin; D005353:Fibronectins; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D008025:Ligases; C497446:VHL protein, human